Anderson Woodrow D 4

4 · Indivior Pharmaceuticals, Inc. · Filed Mar 5, 2026

Form 4

Period: 2026-03-03

Chief Accounting Officer

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2026-03-03+18,364→ 29,657 total
Tax Payment
Common Stock
[F3]
2026-03-03$31.98/sh−8,283$264,890→ 21,374 total
Exercise/Conversion
Common Stock
[F2]
2026-03-03+5,946→ 27,320 total
Tax Payment
Common Stock
[F4]
2026-03-03$31.98/sh−2,682$85,770→ 24,638 total
Exercise/Conversion
Performance Stock Units
[F2][F1]
2026-03-03−23,975→ 0 total
Exercise: $0.00From: 2026-03-03→ Common Stock (23,975 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F5]
2026-03-03−5,946→ 0 total
Exercise: $0.00From: 2026-03-03→ Common Stock (5,946 underlying)

Footnotes (5)

[F1]Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 18,364 shares vested out of the 23,975 target amount.
[F2]Each performance stock unit and restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
[F3]Shares used to satisfy tax withholding obligations associated with the vesting of performance stock units on March 3, 2026.
[F4]Shares used to satisfy tax withholding obligations associated with the vesting of restricted stock units on March 3, 2026.
[F5]This award is fully vested in accordance with its terms, effective March 3, 2026.

Signature

/s/Alice Givens, Power of Attorney|2026-03-05

Documents

1 file